EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Building the Bridge: How B2B Media Is Shaping the Future of Chemical Engineering
The shift is already well underway BB medias value used to be measured in reach how many engineers received your magazine how many clicks your digital...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Forgotten Biology: The Missing Link Behind Trial Outcomes
Clinical trials are often described as the science of uncertainty and that uncertainty is expected It is how evidence is built However not all uncertainty is scientific In many cases it arises when the biological context of an intervention is not carried through into the study population
-
Techno Trends
FORE Biotherapeutics Receives FDA Breakthrough Therapy Designation for Plixorafenib in Brain Cancer
FORE Biotherapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration FDA for its investigational drug plixorafenib developed for the treatment of adult patients with BRAF VEmutated highgrade glioma a severe form of brain cancer
-
Projects
Cambrex Announces $150 Million Expansion across U.S. and European Facilities
Cambrex has revealed significant progress on its expansion initiatives across the United States and Europe These projects are designed to boost capacity for manufacturing complex drugs
-
Research Insights
Gene expression and metadata based identification of key genes for lung cancer, COPD, and IPF using machine learning and statistical models
Lung cancer LC is one of the most prevalent and deadly cancers globally presenting a major public health challenge Patients with chronic obstructive pulmonary disease COPD and idiopathic pulmonary fibrosis
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
-
2
Biosimilar Market Access: Why Execution Gaps Cost Companies Hundreds of Millions
Doug Drysdale
The biosimilar market has generated over USD 56.2 billion in savings since 2015, yet many biosimilar companies systematically underperform on market access. This article examines four critical failure...
-
3
Innovative Technologies Driving Vaccine Research and Production: A Revolution in Healthcare
Kate Williamson
“Innovative Technologies Driving Vaccine Research and Production" explores cutting-edge advancements such as mRNA vaccines, nanotechnology, AI-driven design, and blockchain-enabled supply c...
-
4
Unlocking the Power of Biomarkers: A Comprehensive Guide
Kate Williamson
Biomarkers, spanning genes, proteins, and imaging features, are pivotal in healthcare, offering insights into disease, personalized treatment, and drug development. Challenges include standardization...
-
5
Biotech Boom: How Startups are Driving U.S. Pharma Growth
Kate Williamson
An array of biotech start-ups in America are transforming the pharmacovigilance industry through novel technologies such as CRISPR, Artificial Intelligence, and Precision Medicine. Supported by fundin...
press releasesRead more...
C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)
CRay Therapeutics Chengdu Co Ltd today announced that its Type II Drug Master File DMF for COPPER Cu CHLORIDE FOR RADIOLABELLING has been listed as active by the US Food and Drug Administration
Xcovery Partners with EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.
Xcovery Holdings Inc Xcovery an evidencebased innovationdriven pharmaceutical company today announced an agreement with EVERSANA a leading provider of commercialization services to the global life sciences
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals plc Nasdaq JAZZ today announced that the US Food and Drug Administration FDA accepted for filing with Priority Review the supplemental Biologics License Application sBLA for Ziihera
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Eli Lilly and Company and Ajax Therapeutics Inc a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms MPNs today announced a definitive agreement for Lilly to acquire Ajax
Events Read more...
29 - 30
Apr 2026Pharma Partnering US Summit 2026
Hilton San Diego, USA
05 - 06
May 2026GENAP Summit 2026
Vienna, Austria
06 - 07
May 20262nd Edition MaxPotent Pharma Summit 2026
Milan, Italy
06 - 07
May 202641th pharmacovigilance USA 2026
Boston, USA
07 - 08
May 202621st PPM for Pharma & Biotech
New Jersey, USA
10 - 14
May 2026Respiratory Drug Delivery 2026
The Westin Kierland Phoenix, Arizona, USA
20 - 21
May 2026Pharmacovigilance Europe 2026
London, UK
20 - 22
May 2026PHARMA EURASIA 2026
Pharma & Med Tech Park, Tashkent, Uzbekistan
LATEST NEWSRead more...
Gilead Sciences completes acquisition of Arcellx ahead of potential anito-cel launch
Gilead Sciences has completed its acquisition of Arcellx strengthening its position ahead of a possible commercial launch of anitocabtagene autoleucel anitocel
FDA approves CAPLYTA® (lumateperone) sNDA with new data showing reduced relapse risk in schizophrenia
Johnson Johnson has received approval from the US Food and Drug Administration FDA for a supplemental New Drug Application sNDA for CAPLYTA lumateperone The approval is based on longterm data assessing its safety and effectiveness in preventing relapse in adults with schizophrenia
Helus Pharma Names Jill Conwell Chief People Officer
Helus Pharma a clinicalstage company advancing novel serotonergic agonists appoints experienced HR leader Jill Conwell as Chief People Officer to bolster talent strategy amid key pipeline milestones
OrganaBio and RxMP Therapeutics Partner to Support Manufacturing of RMP-402
OrganaBio and RxMP Therapeutics have announced a manufacturing partnership to advance the development of RMP a novel haemostatic drug candidate designed to control severe bleeding
AbbVie $1.4B NC Manufacturing Expansion
AbbVie is investing billion to establish a new production base in North Carolina enhancing its biopharmaceutical manufacturing capabilities amid growing demand for innovative therapies
BioAegis and Prenosis Collaborate to Advance AI-Driven Precision Medicine in Inflammatory Diseases
BioAegis Therapeutics a clinicalstage biotechnology company focused on inflammatory diseases has entered into a strategic collaboration with Prenosis a specialist in artificial intelligencedriven precision medicine
